Bristol Myers Squibb and Cellares announced Monday a worldwide capacity reservation and supply agreement for the manufacturing of CAR T cell therapies. The transaction is valued at up to $380 million ...
The peripheral T-cell lymphoma treatment market is witnessing steady growth, primarily driven by the increasing incidence, leading to an increased patient population, which fuels the ongoing treatment ...
On April 4, 2024, Bristol Myers Squibb (“BMS”) and 2seventy bio, Inc. announced that the FDA has approved ABECMA (idecabtagene vicleucel) for the treatment of adult patients with relapsed or ...
As he talks about the future of cell therapy, the enthusiasm of Cellares CEO Fabian Gerlinghaus is unmistakable. “There’s about 2,800 cell therapies in development worldwide,” Gerlinghaus said in an ...
At last week’s American Chemical Society Spring meeting, Bristol Myers Squibb Co. discussed the development of a potent, orally bioavailable and highly selective cereblon (CRBN)-mediated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results